Score Overview
Explore the 2021 public Archive ranking →
Where Bristol-Myers Squibb Company has ranked, year by year
Showing 1 year ranking history by HDB Score.
Reached the top 50 on HDB Score in 2 years, the longest run being 1 in a row — but not in 2021.
- BMY
1996: 70.8% · 2021: 57.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 63.88 | — |
1 Year2025-09-26 | $ 42.10 | 51.74% |
5 Years2021-09-28 | $ 48.76 | 31.01% |
10 Years2016-09-28 | $ 38.73 | 64.93% |
20 Years2006-09-28 | $ 11.70 | 446.12% |
30 Years1996-09-27 | $ 7.75 | 8x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 63.88 | $ 42.10 | $ 48.76 | $ 38.73 | $ 11.70 | $ 7.75 |
| Return | — | 51.74% | 31.01% | 64.93% | 446.12% | 8x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 49.18B | $ 9.28B | $ 11.06B |
| 2025 | $ 48.19B | $ 7.05B | $ 10.67B |
| 2024 | $ 48.30B | -$ 8.94B | $ 10.85B |
| 2023 | $ 45.00B | $ 8.02B | $ 12.28B |
| 2022 | $ 46.15B | $ 6.32B | $ 9.25B |
| 2021 | $ 46.38B | $ 6.99B | $ 17.22B |
| 2020 | $ 42.51B | -$ 8.99B | $ 16.45B |
| 2019 | $ 26.14B | $ 3.43B | $ 15.39B |
| 2018 | $ 22.56B | $ 4.92B | $ 8.75B |
| 2017 | $ 20.77B | $ 1.00B | $ 6.81B |
| 2016 | $ 19.42B | $ 4.45B | $ 6.35B |
| 2015 | $ 16.56B | $ 1.56B | $ 4.27B |
| 2014 | $ 15.87B | $ 2.00B | $ 7.43B |
| 2013 | $ 16.38B | $ 2.56B | $ 4.52B |
| 2012 | $ 17.62B | $ 1.96B | $ 2.82B |
| 2011 | $ 21.24B | $ 3.70B | $ 8.73B |
| 2010 | $ 19.48B | $ 3.10B | $ 7.30B |
| 2009 | $ 18.80B | $ 10.61B | $ 8.51B |
| 2008 | $ 20.59B | $ 5.24B | $ 8.26B |
| 2007 | $ 19.34B | $ 2.16B | $ 2.22B |
| 2006 | $ 17.91B | $ 1.58B | $ 4.01B |
| 2005 | $ 19.20B | $ 3.00B | $ 5.79B |
| 2004 | $ 19.38B | $ 2.38B | $ 7.47B |
| 2003 | $ 20.89B | $ 3.10B | $ 5.56B |
| 2002 | $ 18.11B | $ 2.13B | $ 3.98B |
| 2001 | $ 19.42B | $ 5.24B | $ 5.65B |
| 2000 | $ 18.21B | $ 4.71B | $ 3.38B |
| 1999 | $ 20.22B | $ 4.16B | $ 2.95B |
| 1998 | $ 18.28B | $ 3.14B | $ 2.24B |
| 1997 | $ 16.70B | $ 3.20B | $ 1.45B |
| 1996 | $ 15.06B | $ 2.85B | $ 1.68B |
| 1995 | $ 13.76B | $ 1.81B | $ 1.64B |
| 1994 | $ 11.98B | $ 1.84B | $ 1.64B |
| 1993 | $ 11.41B | $ 1.95B | $ 2.42B |
| 1992 | $ 11.15B | $ 1.96B | $ 2.13B |
| 1991 | $ 11.15B | $ 2.05B | $ 1.43B |
| 1990 | $ 10.30B | $ 1.74B | $ 596M |
| 1989 | $ 9.18B | $ 747M | $ 510M |
| 1988 | $ 8.55B | $ 1.25B | $ 2.51B |
| 1987 | $ 7.55B | $ 1.06B | $ 2.34B |
Bristol-Myers Squibb Company fundamental performance
Between 2020 and 2025, revenue grew from $ 42.51B to $ 48.19B and net income went from -$ 8.99B to $ 7.05B. Revenue increased in 2 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 16.56B to $ 48.19B and net income grew from $ 1.56B to $ 7.05B. Revenue increased in 7 of those 10 years; net income in 5.
Bristol-Myers Squibb Company currently holds a 20-year HDB Score of 5.4 out of 10. How the HDB Score is calculated.
Membership
Continue BMY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
